

# Ralph A Defronzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6502131/publications.pdf>

Version: 2024-02-01

147  
papers

26,945  
citations

17440

63  
h-index

10445

139  
g-index

228  
all docs

228  
docs citations

228  
times ranked

24819  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<sc>EDICT</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 899-907.	4.4	15
2	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. <i>American Journal of Human Genetics</i> , 2022, 109, 81-96.	6.2	24
3	Insulin: The master regulator of glucose metabolism. <i>Metabolism: Clinical and Experimental</i> , 2022, 129, 155142.	3.4	78
4	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. <i>Diabetes Care</i> , 2022, 45, 1372-1380.	8.6	4
5	Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155199.	3.4	12
6	Effects of Sustained Hyperglycemia on Skeletal Muscle Lipids in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3177-e3185.	3.6	4
7	<sc>Type 2 diabetes</sc> subgroups and response to glucose-lowering therapy: Results from the <sc>EDICT</sc> and Qatar studies. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1810-1818.	4.4	3
8	Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7667.	4.1	8
9	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , 2021, 70, 204-213.	0.6	15
10	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. <i>Diabetes</i> , 2021, 70, 377-385.	0.6	47
11	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. <i>Diabetes Care</i> , 2021, 44, 433-439.	8.6	29
12	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	8.6	16
13	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154416.	3.4	23
14	Serum carotenoids and Pediatric Metabolic Index predict insulin sensitivity in Mexican American children. <i>Scientific Reports</i> , 2021, 11, 871.	3.3	6
15	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , 2021, 17, 319-334.	9.6	244
16	Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1398-1409.	3.6	16
17	Proximal tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury. <i>JCI Insight</i> , 2021, 6, .	5.0	8
18	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , 2021, 44, 1062-1069.	8.6	25

#	ARTICLE	IF	CITATIONS
19	Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. <i>Diabetes</i> , 2021, 70, 1303-1316.	0.6	22
20	Therapeutic Manipulation of Myocardial Metabolism. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2022-2039.	2.8	40
21	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and <sc>HbA1c of more than 10%: A</sc> post hoc analysis of the <sc>EDICT</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1631-1639.	4.4	2
22	Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. <i>Diabetes Care</i> 2020;43:2296-2302. <i>Diabetes Care</i> , 2021, 44, e98-e99.	8.6	3
23	Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. <i>Nature Communications</i> , 2021, 12, 3505.	12.8	49
24	Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation. <i>Small</i> , 2021, 17, e2008177.	10.0	23
25	Preface: Cardiorenal Considerations for Type 2 Diabetes—Time to Exit the Dark Ages. <i>Diabetes Spectrum</i> , 2021, 34, 214-215.	1.0	0
26	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-13.	1.8	2
27	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. <i>Diabetes Care</i> , 2021, 44, 2115-2123.	8.6	16
28	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <i>Diabetes Spectrum</i> , 2021, 34, 225-234.	1.0	1
29	The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans. <i>Frontiers in Physiology</i> , 2021, 12, 784391.	2.8	13
30	Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1958-1966.	8.6	12
31	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , 2020, 43, 2519-2527.	8.6	3
32	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3226-3233.	3.6	10
33	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020, 63, 2423-2433.	6.3	17
34	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	8.6	15
35	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. <i>Diabetes</i> , 2020, 69, 681-688.	0.6	23
36	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1234-1241.	8.6	30

#	ARTICLE	IF	CITATIONS
37	Culture on a native bone marrow-derived extracellular matrix restores the pancreatic islet basement membrane, preserves islet function, and attenuates islet immunogenicity. <i>FASEB Journal</i> , 2020, 34, 8044-8056.	0.5	9
38	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children. <i>PLoS ONE</i> , 2020, 15, e0240467.	2.5	10
39	Title is missing!. , 2020, 15, e0240467.		0
40	Title is missing!. , 2020, 15, e0240467.		0
41	Title is missing!. , 2020, 15, e0240467.		0
42	Title is missing!. , 2020, 15, e0240467.		0
43	Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4230.	4.1	3
44	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , 2019, 40, 1447-1467.	20.1	210
45	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 133-143.	2.0	155
46	Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2842-2850.	3.6	18
47	Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. <i>Nature</i> , 2019, 570, 71-76.	27.8	248
48	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , 2019, 4, .	5.0	15
49	Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2019, 17, 153-163.	1.7	39
50	Genetic and environmental (physical fitness and sedentary activity) interaction effects on cardiometabolic risk factors in Mexican American children and adolescents. <i>Genetic Epidemiology</i> , 2018, 42, 378-393.	1.3	7
51	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. <i>Diabetes</i> , 2018, 67, 1182-1189.	0.6	44
52	Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, <i>Papio sp.</i> . <i>PLoS ONE</i> , 2018, 13, e0208757.	2.5	2
53	Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. <i>Diabetes</i> , 2018, 67, 2507-2517.	0.6	26
54	Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E229-E239.	3.5	15

#	ARTICLE	IF	CITATIONS
55	Ectopic BAT mUCP-1 overexpression in SKM by delivering a BMP7/PRDM16/PGC-1a gene cocktail or single PRMD16 using non-viral UTMD gene therapy. <i>Gene Therapy</i> , 2018, 25, 497-509.	4.5	7
56	Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option?. <i>Annals of Translational Medicine</i> , 2018, 6, S95-S95.	1.7	3
57	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. <i>Diabetes Care</i> , 2017, 40, 325-331.	8.6	32
58	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. <i>Diabetes</i> , 2017, 66, 815-822.	0.6	234
59	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 809-813.	4.4	61
60	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 1999-2006.	0.6	67
61	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1353-1362.	4.4	120
62	Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2162-2170.	3.6	12
63	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	8.6	109
64	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves $\beta$ -Cell Function in Subjects With Impaired Fasting Glucose. <i>Diabetes</i> , 2017, 66, 2495-2502.	0.6	21
65	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	2.1	362
66	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , 2017, 13, 11-26.	9.6	398
67	A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 2903-2914.	0.6	52
68	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	8.6	45
69	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , 2017, 40, 1121-1127.	8.6	43
70	Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. <i>Scientific Data</i> , 2017, 4, 170179.	5.3	31
71	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , 2016, 39, 198-205.	8.6	240
72	The genetic architecture of type 2 diabetes. <i>Nature</i> , 2016, 536, 41-47.	27.8	952

#	ARTICLE	IF	CITATIONS
73	Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype. <i>Genomics Data</i> , 2016, 8, 25-36.	1.3	37
74	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , 2016, 59, 1645-1654.	6.3	95
75	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016, 39, 717-725.	8.6	244
76	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. <i>Diabetes Care</i> , 2016, 39, 1804-1810.	8.6	15
77	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. <i>Hepatology</i> , 2016, 64, 2028-2037.	7.3	78
78	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15019.	30.5	1,308
79	Transcriptomic Identification of ADH1B as a Novel Candidate Gene for Obesity and Insulin Resistance in Human Adipose Tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). <i>PLoS ONE</i> , 2015, 10, e0119941.	2.5	35
80	Nox2 Mediates Skeletal Muscle Insulin Resistance Induced by a High Fat Diet. <i>Journal of Biological Chemistry</i> , 2015, 290, 13427-13439.	3.4	63
81	Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. <i>Diabetes Care</i> , 2015, 38, 384-393.	8.6	241
82	Dapagliflozin Lowers Plasma Glucose Concentration and Improves $\beta$ -Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1927-1932.	3.6	133
83	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F889-F900.	2.7	113
84	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2819-2833.	1.8	20
85	Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates. <i>American Journal of Pathology</i> , 2015, 185, 139-150.	3.8	16
86	Successful $\beta$ cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1. <i>Cell Cycle</i> , 2014, 13, 1145-1151.	2.6	34
87	The Disposition Index Does Not Reflect $\beta$ -Cell Function in IGT Subjects Treated With Pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3774-3781.	3.6	34
88	Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. <i>Diabetes Care</i> , 2014, 37, 1706-1711.	8.6	11
89	Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 306, C202-C211.	4.6	15
90	APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor. <i>Cell Reports</i> , 2014, 7, 1227-1238.	6.4	107

#	ARTICLE	IF	CITATIONS
91	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 509-514.	8.2	661
92	Prevention of Diabetes With Pioglitazone in ACT NOW. <i>Diabetes</i> , 2013, 62, 3920-3926.	0.6	83
93	Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2756-2762.	8.6	52
94	Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 393-399.	2.4	97
95	In Vivo Actions of Peroxisome Proliferator-Activated Receptors. <i>Diabetes Care</i> , 2013, 36, S162-S174.	8.6	94
96	Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3169-3176.	8.6	233
97	Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans. <i>Diabetes</i> , 2013, 62, 3324-3328.	0.6	198
98	Distinct $\beta$ -Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance. <i>Diabetes</i> , 2012, 61, 447-453.	0.6	96
99	Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. <i>New England Journal of Medicine</i> , 2011, 364, 1104-1115.	27.0	646
100	Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. <i>Acta Diabetologica</i> , 2011, 48, 209-217.	2.5	55
101	Role of Glycated Hemoglobin in the Prediction of Future Risk of T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2596-2600.	3.6	45
102	Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes. <i>Endocrine Reviews</i> , 2011, 32, 515-531.	20.1	344
103	Effects of Exenatide Plus Rosiglitazone on $\beta$ -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin. <i>Diabetes Care</i> , 2010, 33, 951-957.	8.6	100
104	Pathogenesis of Insulin Resistance in Skeletal Muscle. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-19.	3.0	441
105	Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1916-1923.	3.6	72
106	Genome-Wide Linkage Scan for Genes Influencing Plasma Triglyceride Levels in the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , 2009, 58, 279-284.	0.6	23
107	Pancreatic islet amyloidosis, $\beta$ -cell apoptosis, and $\beta$ -cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13992-13997.	7.1	147
108	Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. <i>Cardiovascular Diabetology</i> , 2009, 8, 22.	6.8	34

#	ARTICLE	IF	CITATIONS
109	From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. <i>Diabetes</i> , 2009, 58, 773-795.	0.6	2,251
110	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2943-2952.	1.9	341
111	Decreased Non-Insulin-Dependent Glucose Clearance Contributes to the Rise in Fasting Plasma Glucose in the Nondiabetic Range. <i>Diabetes Care</i> , 2008, 31, 311-315.	8.6	30
112	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 294, E846-E852.	3.5	144
113	Physiological and Molecular Determinants of Insulin Action in the Baboon. <i>Diabetes</i> , 2008, 57, 899-908.	0.6	75
114	Thiazolidinediones improve $\beta$ -cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E871-E883.	3.5	167
115	The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1249-1255.	3.6	219
116	What Is the Best Predictor of Future Type 2 Diabetes?. <i>Diabetes Care</i> , 2007, 30, 1544-1548.	8.6	310
117	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	1.3	500
118	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2006, 355, 2297-2307.	27.0	1,584
119	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 329-341.	2.4	21
120	Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance: Results From the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , 2006, 55, 1430-1435.	0.6	429
121	Contributions of $\beta$ -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>Diabetes Care</i> , 2006, 29, 1130-1139.	8.6	382
122	Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients. <i>Diabetes</i> , 2005, 54, 3148-3153.	0.6	162
123	$\beta$ -Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 493-500.	3.6	470
124	Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients. <i>Diabetes</i> , 2003, 52, 1943-1950.	0.6	128
125	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 2461-2474.	0.6	447
126	Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1111-1119.	3.4	76



#	ARTICLE	IF	CITATIONS
127	Time course of insulin action on tissue-specific intracellular glucose metabolism in normal rats. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E642-E650.	3.5	18
128	Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E998-E1001.	3.5	20
129	Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance. Journal of the Society for Gynecologic Investigation, 1995, 2, 708-715.	1.7	31
130	Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1995, 333, 541-549.	27.0	1,213
131	Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease. Diabetes Care, 1991, 14, 173-194.	8.6	3,723
132	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. Hepatology, 1991, 14, 432-441.	7.3	46
133	Measurement of abdominal fat with T1-weighted MR images. Journal of Magnetic Resonance Imaging, 1991, 1, 363-369.	3.4	67
134	Effect of Strict Glycemic Control on Renal Hemodynamic Response to Amino Acids and Renal Enlargement in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1991, 324, 1626-1632.	27.0	195
135	Mechanism of Metformin Action in Obese and Lean Noninsulin-Dependent Diabetic Subjects*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 1294-1301.	3.6	363
136	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. Hepatology, 1991, 14, 432-441.	7.3	2
137	Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by <sup>13</sup> C Nuclear Magnetic Resonance Spectroscopy. New England Journal of Medicine, 1990, 322, 223-228.	27.0	1,181
138	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism: Clinical and Experimental, 1989, 38, 387-395.	3.4	492
139	Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes/metabolism Reviews, 1988, 4, 727-747.	0.3	117
140	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism: Clinical and Experimental, 1988, 37, 79-85.	3.4	268
141	Influence of hyperinsulinaemia on intracellular amino acid levels and amino acid exchange across splanchnic and leg tissues in uraemia. Clinical Science, 1988, 74, 155-163.	4.3	57
142	Regulation of hepatic glucose metabolism in humans. Diabetes/metabolism Reviews, 1987, 3, 415-459.	0.3	139
143	Announcing a new quarterly journal from Wiley, New York. Diabetic Medicine, 1985, 2, 216-216.	2.3	0
144	Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. European Journal of Endocrinology, 1981, 98, 81-86.	3.7	88

#	ARTICLE	IF	CITATIONS
145	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , 1980, 29, 28-35.	3.4	117
146	Epinephrine-induced Insulin Resistance in Man. <i>Journal of Clinical Investigation</i> , 1980, 65, 717-721.	8.2	480
147	Mechanism of Metformin Action in Obese and Lean Noninsulin-Dependent Diabetic Subjects. , 0, .		1